371 related articles for article (PubMed ID: 27620280)
1.
Lips EH; Debipersad RD; Scheerman CE; Mulder L; Sonke GS; van der Kolk LE; Wesseling J; Hogervorst FB; Nederlof PM
Clin Cancer Res; 2017 Mar; 23(5):1236-1241. PubMed ID: 27620280
[No Abstract] [Full Text] [Related]
2. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy.
Vollebergh MA; Lips EH; Nederlof PM; Wessels LF; Wesseling J; Vd Vijver MJ; de Vries EG; van Tinteren H; Jonkers J; Hauptmann M; Rodenhuis S; Linn SC
Breast Cancer Res; 2014 May; 16(3):R47. PubMed ID: 24887359
[TBL] [Abstract][Full Text] [Related]
3. Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA; Brandwijk KI; Devilee P; Wesseling J; Hogervorst FB; Verhoef S; Nederlof PM
Breast Cancer Res Treat; 2012 Apr; 132(2):379-89. PubMed ID: 20614180
[TBL] [Abstract][Full Text] [Related]
4. Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier.
Chen Y; Wang Y; Salas LA; Miller TW; Mark K; Marotti JD; Kettenbach AN; Cheng C; Christensen BC
Breast Cancer Res; 2019 Jan; 21(1):14. PubMed ID: 30683142
[TBL] [Abstract][Full Text] [Related]
5. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A.
Mote PA; Leary JA; Avery KA; Sandelin K; Chenevix-Trench G; Kirk JA; Clarke CL;
Genes Chromosomes Cancer; 2004 Mar; 39(3):236-48. PubMed ID: 14732925
[TBL] [Abstract][Full Text] [Related]
6. BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
Maxwell KN; Wubbenhorst B; Wenz BM; De Sloover D; Pluta J; Emery L; Barrett A; Kraya AA; Anastopoulos IN; Yu S; Jiang Y; Chen H; Zhang NR; Hackman N; D'Andrea K; Daber R; Morrissette JJD; Mitra N; Feldman M; Domchek SM; Nathanson KL
Nat Commun; 2017 Aug; 8(1):319. PubMed ID: 28831036
[TBL] [Abstract][Full Text] [Related]
7. DNA damage response markers are differentially expressed in BRCA-mutated breast cancers.
Aleskandarany M; Caracappa D; Nolan CC; Macmillan RD; Ellis IO; Rakha EA; Green AR
Breast Cancer Res Treat; 2015 Feb; 150(1):81-90. PubMed ID: 25690937
[TBL] [Abstract][Full Text] [Related]
8. Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer.
Danzinger S; Tan YY; Rudas M; Kastner MT; Weingartshofer S; Muhr D; Singer CF
BMC Cancer; 2019 Jul; 19(1):695. PubMed ID: 31307407
[TBL] [Abstract][Full Text] [Related]
9. Association of BRCA1/2 defects with genomic scores predictive of DNA damage repair deficiency among breast cancer subtypes.
Timms KM; Abkevich V; Hughes E; Neff C; Reid J; Morris B; Kalva S; Potter J; Tran TV; Chen J; Iliev D; Sangale Z; Tikishvili E; Perry M; Zharkikh A; Gutin A; Lanchbury JS
Breast Cancer Res; 2014 Dec; 16(6):475. PubMed ID: 25475740
[TBL] [Abstract][Full Text] [Related]
10. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.
Foulkes WD; Metcalfe K; Sun P; Hanna WM; Lynch HT; Ghadirian P; Tung N; Olopade OI; Weber BL; McLennan J; Olivotto IA; Bégin LR; Narod SA
Clin Cancer Res; 2004 Mar; 10(6):2029-34. PubMed ID: 15041722
[TBL] [Abstract][Full Text] [Related]
11. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
[TBL] [Abstract][Full Text] [Related]
12. Genomic profiling of CHEK2*1100delC-mutated breast carcinomas.
Massink MP; Kooi IE; Martens JW; Waisfisz Q; Meijers-Heijboer H
BMC Cancer; 2015 Nov; 15():877. PubMed ID: 26553136
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of tumor-infiltrating lymphocytes and association with prognosis in BRCA-mutated breast cancer.
Sønderstrup IMH; Jensen MB; Ejlertsen B; Eriksen JO; Gerdes AM; Kruse TA; Larsen MJ; Thomassen M; Laenkholm AV
Acta Oncol; 2019 Mar; 58(3):363-370. PubMed ID: 30614364
[TBL] [Abstract][Full Text] [Related]
14. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
Oldenburg RA; Kroeze-Jansema K; Meijers-Heijboer H; van Asperen CJ; Hoogerbrugge N; van Leeuwen I; Vasen HF; Cleton-Jansen AM; Kraan J; Houwing-Duistermaat JJ; Morreau H; Cornelisse CJ; Devilee P
Clin Cancer Res; 2006 Mar; 12(6):1693-700. PubMed ID: 16551851
[TBL] [Abstract][Full Text] [Related]
15. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
[TBL] [Abstract][Full Text] [Related]
16. Intratumor Heterogeneity of Homologous Recombination Deficiency in Primary Breast Cancer.
von Wahlde MK; Timms KM; Chagpar A; Wali VB; Jiang T; Bossuyt V; Saglam O; Reid J; Gutin A; Neff C; Lanchbury JS; Hatzis C; Hofstatter E; Pusztai L
Clin Cancer Res; 2017 Mar; 23(5):1193-1199. PubMed ID: 27601588
[No Abstract] [Full Text] [Related]
17. Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma.
Rio PG; Pernin D; Bay JO; Albuisson E; Kwiatkowski F; De Latour M; Bernard-Gallon DJ; Bignon YJ
Int J Oncol; 1998 Oct; 13(4):849-53. PubMed ID: 9735416
[TBL] [Abstract][Full Text] [Related]
18. Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.
Metcalfe K; Lynch HT; Foulkes WD; Tung N; Kim-Sing C; Olopade OI; Eisen A; Rosen B; Snyder C; Gershman S; Sun P; Narod SA
JAMA Oncol; 2015 Jun; 1(3):306-13. PubMed ID: 26181175
[TBL] [Abstract][Full Text] [Related]
19. Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer.
Murria Estal R; Palanca Suela S; de Juan Jiménez I; Alenda Gonzalez C; Egoavil Rojas C; García-Casado Z; López Guerrero JA; Juan Fita MJ; Sánchez Heras AB; Segura Huerta Á; Santaballa Bertrán A; Chirivella González I; Llop García M; Pérez Simó G; Barragán González E; Bolufer Gilabert P
Fam Cancer; 2016 Apr; 15(2):193-200. PubMed ID: 26723934
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic exploitation of tumor cell defects in homologous recombination.
Powell SN; Kachnic LA
Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
